Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has demonstrated that it can predict the outcome of Phase II to Phase III clinical trial success using its proprietary transformer-based AI clinical trial prediction tool called inClinico with a high degree of accuracy.
Insmed, Merus announce public offerings; AI startup raises $13M seed round
Plus, news about AEON Biopharma, Bio-Thera and STADA: Insmed to raise $500M in public offering: The startup launched the offering after … Sign up to
May 30, 2024